Six Questions With Dr. Matthew Memoli
By Brooke Worthing
Thursday, August 22, 2019
We all know flu season as the time of year where people are loading up on hand sanitizer and heading to the doctor for their flu shot. However, many underestimate the severity of the flu. During a typical flu season, five to twenty percent of Americans fall ill, leading to more than 200,000 hospitalizations and 36,000 deaths. Because of this serious threat to the public, the IRP has a long track record of researching vaccines, antivirals, diagnostics, and other resources in an effort to prevent individuals from catching the flu and improve care for those who do.
By Michele Lyons
Monday, July 1, 2019
Summer has finally arrived, and it's once again time to shine some light on NIH's rich history. Over the past couple months, NIH has celebrated several important anniversaries, including the 20th birthday of NIH's Vaccine Research Center and the 70th anniversary of the NIH Record newsletter. Read on to learn more about these milestones and other fun facts and intriguing objects from NIH's past!
A Conversation with Dr. Paolo Lusso
By Brooke Worthing
Thursday, June 27, 2019
First discovered in 1981, human immunodeficiency virus, or HIV, caused one of the most deadly and persistent epidemics in history. HIV destroys CD4+ T cells, a type of white blood cell essential for fighting infection. In doing so, HIV destroys the body’s ability to fight off disease, which often leads to life-threatening consequences.
Today, medications have allowed people living with HIV to lead healthier lives. However, HIV still remains a major public health concern and continues to be studied by researchers within the IRP and beyond.
IRP research has produced findings essential to the development of current HIV treatments and tools for diagnosis. However, there is still a lot left to learn. One recent IRP contribution to HIV research was a 2017 study led by IRP senior investigator Paolo Lusso, M.D., Ph.D., which suggests that treatments targeting a protein called integrin α4β7 could potentially become an addition to current treatment options for those with HIV, or provide new measures to prevent infection.
By Michele Lyons
Wednesday, January 2, 2019
The waning weeks of 2018 were busy ones in the Office of NIH History. We're constantly receiving and cataloguing new donations of historic equipment, images, publications, and more. It’s time to see what our donors have given us lately!
"I thought why could you not invert the concept? Instead of laying down hundreds or thousands of probes, how about laying down hundreds or thousands of tissue spots and probing them one antibody or gene probe at a time," remembers Dr. Juha Kononen of the National Human Genome Research Institute (NHGRI) about his idea that led to this prototype manual microarray. Tissue array technology performs rapid molecular profiling of hundreds of normal and pathological tissue specimens or cultured cells. Dr. Kononen worked with Drs. Olli Kallioniemi and Stephen B. Leighton to design this tissue microarray which was initially used in the Cancer Genomics Branch. Now, the National Cancer Institute's Tissue Array Research Program (TARP) develops and distributes multi-tumor tissue microarray slides to cancer researchers based on this technology. The quote comes from a 2002 article published in The Scientist.
By Michele Lyons
Friday, November 9, 2018
Scientific research is not all writing grants, giving presentations, and publishing papers. There are real risks to probing the secrets of biology, and sometimes scientists lose their lives during the course of their work. In honor of Veterans Day, we woud like to commemorate NIH staff who made the ultimate sacrifice in pursuit of knowledge that can help us prevent and treat diseases that impact so many lives.
By Michele Lyons
Wednesday, January 3, 2018
We haven’t shared recent additions to the NIH Stetten Museum collection in a long time, so you’re in for a treat this month!
By IRP Staff Blogger
Tuesday, November 15, 2016
The surprising results of an animal study are raising hopes for a far simpler treatment regimen for people infected with the AIDS-causing human immunodeficiency virus (HIV). Currently, HIV-infected individuals can live a near normal life span if, every day, they take a complex combination of drugs called antiretroviral therapy (ART). The bad news is if they stop ART, the small amounts of HIV that still lurk in their bodies can bounce back and infect key immune cells, called CD4 T cells, resulting in life-threatening suppression of their immune systems.
